[{"orgOrder":0,"company":"Metagenomi","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna and Metagenomi Establish Collaboration to Develop Next-Generation In Vivo Gene Editing Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"In-vivo Gene Editing Therapeutics","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Metagenomi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Metagenomi \/ Moderna Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Metagenomi.."},{"orgOrder":0,"company":"Metagenomi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Metagenomi to Present New Preclinical Data at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"TCR-cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Metagenomi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Metagenomi \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Metagenomi.."},{"orgOrder":0,"company":"Metagenomi","sponsor":"Affini-T Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Affini-T Therapeutics & Metagenomi Announce Next-Generation Gene Editing Partnership to Advance Cell Therapies for Solid Tumor Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Partnership","leadProduct":"AFNT-111","moa":"KRAS G12V","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Metagenomi","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Metagenomi \/ Affini-T Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Metagenomi.."},{"orgOrder":0,"company":"Metagenomi","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$80.0 million","newsHeadline":"Ionis Partners with Metagenomi to Add Gene Editing to Its Broad Technology Platform","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Collaboration","leadProduct":"RNA-based Therapy","moa":"","url1":"","url2":"","graph1":"Technology","graph2":"Discovery","graph3":"Metagenomi","amount2":0,"therapeuticAreaNew":"Technology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Metagenomi \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Metagenomi.."},{"orgOrder":0,"company":"Metagenomi","sponsor":"Novo Hold\u00adings","pharmaFlowCategory":"D","amount":"$275.0 million","upfrontCash":"Undisclosed","newsHeadline":"Metagenomi Closes Oversubscribed Series B Financing Totaling $275M to Advance Lead Therapeutic Programs into Clinical Development and Grow Genetic Medicines Pipeline","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Metagenomi","amount2":0.28000000000000003,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Metagenomi \/ Novo Hold\u00adings","highestDevelopmentStatusID":"4","companyTruncated":"Metagenomi.."},{"orgOrder":0,"company":"Metagenomi","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$86.9 million","upfrontCash":"Undisclosed","newsHeadline":"Gene Editing Biotech Metagenomi Plans Modest $87M IPO","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Metagenomi","amount2":0.089999999999999997,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Metagenomi \/ J.P. Morgan","highestDevelopmentStatusID":"4","companyTruncated":"Metagenomi.."},{"orgOrder":0,"company":"Metagenomi","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$93.7 million","upfrontCash":"Undisclosed","newsHeadline":"Metagenomi Announces Pricing of Initial Public Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Metagenomi","amount2":0.089999999999999997,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Metagenomi \/ J.P. Morgan","highestDevelopmentStatusID":"4","companyTruncated":"Metagenomi.."},{"orgOrder":0,"company":"Metagenomi","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$93.7 million","upfrontCash":"Undisclosed","newsHeadline":"Metagenomi Announces Closing of Initial Public Offering","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Public Offering","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Metagenomi","amount2":0.089999999999999997,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Metagenomi \/ J.P. Morgan","highestDevelopmentStatusID":"4","companyTruncated":"Metagenomi.."},{"orgOrder":0,"company":"Metagenomi","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Metagenomi to Regain Full Development Rights to its Wholly-owned Base Editing and RIGS Systems","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Termination","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Metagenomi","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Metagenomi \/ Moderna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Metagenomi.."}]

Find Clinical Drug Pipeline Developments & Deals by Metagenomi

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : Metagenomi and Moderna have mutually agreed to terminate their collaboration on primary hyperoxaluria type 1 (PH1), and rights to develop the PH1 program, as well as all other rights granted under the col...

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          May 01, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Partner/Sponsor/Collaborator : Moderna Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Termination

                          blank

                          02

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Partner/Sponsor/Collaborator : J.P. Morgan

                          Deal Size : $93.7 million

                          Deal Type : Public Offering

                          Details : The net proceeds will be used for continued research and development of next-generation gene editing technology to develop company's therapeutic portfolio, including metabolic disease, hemophilia A, cardi...

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          February 13, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Partner/Sponsor/Collaborator : J.P. Morgan

                          Deal Size : $93.7 million

                          Deal Type : Public Offering

                          blank

                          03

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Partner/Sponsor/Collaborator : J.P. Morgan

                          Deal Size : $93.7 million

                          Deal Type : Public Offering

                          Details : The net proceeds will be used for continued research and development of next-generation gene editing technology to develop company's therapeutic portfolio, including metabolic disease, hemophilia A, cardi...

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          February 08, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Partner/Sponsor/Collaborator : J.P. Morgan

                          Deal Size : $93.7 million

                          Deal Type : Public Offering

                          blank

                          04

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Partner/Sponsor/Collaborator : J.P. Morgan

                          Deal Size : $86.9 million

                          Deal Type : Public Offering

                          Details : The net proceeds will be used for continued research and development of next-generation gene editing technology to develop company's therapeutic portfolio, including metabolic disease, hemophilia A, cardi...

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          February 05, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Partner/Sponsor/Collaborator : J.P. Morgan

                          Deal Size : $86.9 million

                          Deal Type : Public Offering

                          blank

                          05

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Partner/Sponsor/Collaborator : Novo Hold­ings

                          Deal Size : $275.0 million

                          Deal Type : Series B Financing

                          Details : Com­pa­ny plans to nom­i­nate addi­tion­al ther­a­peu­tic tar­gets to its pro­pri­etary genet­ic med­i­cines pipeline, fueled by its auto­mat­ed dis­cov­ery engine and ver­sa­tile gen...

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          January 05, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Partner/Sponsor/Collaborator : Novo Hold­ings

                          Deal Size : $275.0 million

                          Deal Type : Series B Financing

                          blank

                          06

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : CRISPR gene editing is a technology that modifies the sequence of DNA in cells utilizing a specific RNA-guided nuclease (Cas enzyme). Gene editing enzymes act as molecular word processors to correct the g...

                          Product Name : Undisclosed

                          Product Type : Large molecule

                          Upfront Cash : $80.0 million

                          November 14, 2022

                          Lead Product(s) : RNA-based Therapy

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery

                          Partner/Sponsor/Collaborator : Ionis Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          07

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : The partnership will leverage Metagenomi’s proprietary gene editing systems to complement Affini-T’s state-of-the-art TCR discovery and synthetic biology platforms to generate groundbreaking cell ther...

                          Product Name : AFNT-111

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          June 15, 2022

                          Lead Product(s) : AFNT-111

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Partner/Sponsor/Collaborator : Affini-T Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          08

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Lead Product(s) : TCR-cell Therapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : CRISPR-associated gene-editing systems (Immuno-Oncology (TCR)- Solid tumor) discovered in metagenomic samples enable efficient genome engineering in multiple primary immune cell types.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          May 05, 2022

                          Lead Product(s) : TCR-cell Therapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : The collaboration will combine Metagenomi’s next-generation CRISPR-based and other novel gene editing systems with Moderna’s mRNA and LNP technologies to accelerate the development of in vivo gene edi...

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          November 02, 2021

                          Lead Product(s) : In-vivo Gene Editing Therapeutics

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Discovery Platform

                          Partner/Sponsor/Collaborator : Moderna Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank